620 research outputs found
Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
Alpha-particle radiopharmaceutical therapy (αRPT) is currently enjoying increasing attention as a viable alternative to chemotherapy for targeting of disseminated micrometastatic disease. In theory, αRPT can be personalized through pre-therapeutic imaging and dosimetry. However, in practice, given the particularities of α-particle emissions, a dosimetric methodology that accurately predicts the thresholds for organ toxicity has not been reported. This is in part due to the fact that the biological effects caused by α-particle radiation differ markedly from the effects caused by traditional external beam (photon or electron) radiation or β-particle emitting radiopharmaceuticals. The concept of relative biological effectiveness (RBE) is used to quantify the ratio of absorbed doses required to achieve a given biological response with alpha particles versus a reference radiation (typically a beta emitter or external beam radiation). However, as conventionally defined, the RBE varies as a function of absorbed dose and therefore a single RBE value is limited in its utility because it cannot be used to predict response over a wide range of absorbed doses. Therefore, efforts are underway to standardize bioeffect modeling for different fractionation schemes and dose rates for both nuclear medicine and external beam radiotherapy. Given the preponderant use of external beams of radiation compared to nuclear medicine in cancer therapy, the more clinically relevant quantity, the 2 Gy equieffective dose, EQD2(α/β), has recently been proposed by the ICRU. In concert with EQD2(α/β), we introduce a new, redefined RBE quantity, named RBE2(α/β), as the ratio of the two linear coefficients that characterize the α particle absorbed dose-response curve and the low-LET megavoltage photon 2 Gy fraction equieffective dose-response curve. The theoretical framework for the proposed new formalism is presented along with its application to experimental data obtained from irradiation of a breast cancer cell line. Radiobiological parameters are obtained using the linear quadratic model to fit cell survival data for MDA-MB-231 human breast cancer cells that were irradiated with either α particles or a single fraction of low-LET (137)Cs γ rays. From these, the linear coefficient for both the biologically effective dose (BED) and the EQD2(α/β) response lines were derived for fractionated irradiation. The standard RBE calculation, using the traditional single fraction reference radiation, gave RBE values that ranged from 2.4 for a surviving fraction of 0.82-6.0 for a surviving fraction of 0.02, while the dose-independent RBE2(4.6) value was 4.5 for all surviving fraction values. Furthermore, bioeffect modeling with RBE2(α/β) and EQD2(α/β) demonstrated the capacity to predict the surviving fraction of cells irradiated with acute and fractionated low-LET radiation, α particles and chronic exponentially decreasing dose rates of low-LET radiation. RBE2(α/β) is independent of absorbed dose for α-particle emitters and it provides a more logical framework for data reporting and conversion to equieffective dose than the conventional dose-dependent definition of RBE. Moreover, it provides a much needed foundation for the ongoing development of an α-particle dosimetry paradigm and will facilitate the use of tolerance dose data available from external beam radiation therapy, thereby helping to develop αRPT as a single modality as well as for combination therapies
Bortezomib-induced enzyme-targeted radiotherapy (BETR) for AIDS-related malignancies: efficacy assessment by Monte Carlo and dosimetry modeling
Molecular Dynamics Test of the Stress-Thermal Rule in Polyethylene and Polystyrene Entangled Melts
Anisotropic thermal transport induced by deformation
and the linear relation between the thermal conductivity and
stress tensors, also known as the stress-thermal rule (STR), are
tested via molecular dynamics simulations in well-entangled linear
polyethylene (PE) and polystyrene (PS) melts subjected to
extensional flow. We propose a method to determine the stress
in deformed molecular melts, a key component missing in prior
simulation studies on thermal transport in polymers that prevented
verification of the STR. We compare our results with available data
from previous experimental and simulation studies. Thermal
conductivity (TC) is found to increase (decrease) in the direction
parallel (perpendicular) to the imposed stretch. We find that the STR is valid for both PE and PS over a wide range of deformation
rates and stress levels. In direct agreement with experimental evidence and the STR, we observe that for a given strain, the anisotropy
in TC increases with the strain rate. Surprisingly, our results for PE question the universal behavior with respect to polymer
chemistry suggested by experiments by showing a significantly higher proportionality constant (the stress-thermal coefficient)
between stress and anisotropy in TC. We argue that this discrepancy can be explained by the high degree of entanglement
interactions in PE affecting the transport of energy at the molecular level. Our conjecture is tested by studying an entangled linear PS
melt, a polymer with a much lower entanglement plateau, for which thermal transport experimental results are available. For PS, the
normalized stress-thermal coefficient is found to be commensurate with the experimental value. Finally, we test the fundamental
molecular hypothesis of preferential energy transport along the backbone of polymer chains used to formulate the STR, which was
prompted by early experimental evidence showing an increase in TC with chain length. We are able to establish that the increase in
TC with chain length in PE melts fades as the system becomes entangled (i.e., TC remains constant beyond the critical
entanglement chain length that marks the transition to entanglement-dominated rheological behavior). Our findings are of key
importance in developing robust molecular-to-continuum methodologies for the study of nonisothermal macroscopic flows that are
extremely relevant to polymer manufacturing processes.European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie IF MTCIATTP 750985
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct monte carlo methods.
Dose kernel convolution (DK) methods have been proposed to speed up absorbed dose calculations in molecular radionuclide therapy. Our aim was to evaluate the impact of tissue density heterogeneities (TDH) on dosimetry when using a DK method and to propose a simple density-correction method.
METHODS: This study has been conducted on 3 clinical cases: case 1, non-Hodgkin lymphoma treated with (131)I-tositumomab; case 2, a neuroendocrine tumor treatment simulated with (177)Lu-peptides; and case 3, hepatocellular carcinoma treated with (90)Y-microspheres. Absorbed dose calculations were performed using a direct Monte Carlo approach accounting for TDH (3D-RD), and a DK approach (VoxelDose, or VD). For each individual voxel, the VD absorbed dose, D(VD), calculated assuming uniform density, was corrected for density, giving D(VDd). The average 3D-RD absorbed dose values, D(3DRD), were compared with D(VD) and D(VDd), using the relative difference Δ(VD/3DRD). At the voxel level, density-binned Δ(VD/3DRD) and Δ(VDd/3DRD) were plotted against ρ and fitted with a linear regression.
RESULTS: The D(VD) calculations showed a good agreement with D(3DRD). Δ(VD/3DRD) was less than 3.5%, except for the tumor of case 1 (5.9%) and the renal cortex of case 2 (5.6%). At the voxel level, the Δ(VD/3DRD) range was 0%-14% for cases 1 and 2, and -3% to 7% for case 3. All 3 cases showed a linear relationship between voxel bin-averaged Δ(VD/3DRD) and density, ρ: case 1 (Δ = -0.56ρ + 0.62, R(2) = 0.93), case 2 (Δ = -0.91ρ + 0.96, R(2) = 0.99), and case 3 (Δ = -0.69ρ + 0.72, R(2) = 0.91). The density correction improved the agreement of the DK method with the Monte Carlo approach (Δ(VDd/3DRD) < 1.1%), but with a lesser extent for the tumor of case 1 (3.1%). At the voxel level, the Δ(VDd/3DRD) range decreased for the 3 clinical cases (case 1, -1% to 4%; case 2, -0.5% to 1.5%, and -1.5% to 2%). No more linear regression existed for cases 2 and 3, contrary to case 1 (Δ = 0.41ρ - 0.38, R(2) = 0.88) although the slope in case 1 was less pronounced.
CONCLUSION: This study shows a small influence of TDH in the abdominal region for 3 representative clinical cases. A simple density-correction method was proposed and improved the comparison in the absorbed dose calculations when using our voxel S value implementation
Identification of medium mass (A=60-80) ejectiles from 15 MeV/nucleon peripheral heavy-ion collisions with the MAGNEX large-acceptance spectrometer
An approach to identify medium-mass ejectiles from peripheral heavy-ion
reactions in the energy region of 15 MeV/nucleon is developed for data obtained
with a large acceptance magnetic spectrometer. This spectrometer is equipped
with a focal plane multidetector, providing position, angle, energy loss and
residual energy of the ions along with measurement of the time-of-flight. Ion
trajectory reconstruction is performed at high order and ion mass is obtained
with a resolution of better than 1/150. For the unambiguous particle
identification however, the reconstruction of both the atomic number Z and the
ionic charge q of the ions is critical and it is suggested, within this work,
to be performed prior to mass identification. The new proposed method was
successfully applied to MAGNEX spectrometer data, for identifying neutron-rich
ejectiles related to multinucleon transfer generated in the 70Zn+ 64Ni
collision at 15 MeV/nucleon. This approach opens up the possibility of
employing heavy-ion reactions with medium-mass beams below the Fermi energy
(i.e., in the region 15-25 MeV/nucleon) in conjunction with large acceptance
ray tracing spectrometers, first, to study the mechanism(s) of nucleon transfer
in these reactions and, second, to produce and study very neutron-rich or even
new nuclides in previously unexplored regions of the nuclear landscape.Comment: 6 pages, 6figure
Comparison of I-131 Radioimmunotherapy Tumor Dosimetry: Unit Density Sphere Model Versus Patient-Specific Monte Carlo Calculations
High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical setting, despite the fact that they are considered more accurate than traditional methods. The goal of this study was to compare mean tumor absorbed dose estimates using the unit density sphere model incorporated in OLINDA with previously reported dose estimates from Monte Carlo simulations using the dose planning method (DPMMC) particle transport algorithm. The dataset (57 tumors, 19 lymphoma patients who underwent SPECT/CT imaging during I-131 radioimmunotherapy) included tumors of varying size, shape, and contrast. OLINDA calculations were first carried out using the baseline tumor volume and residence time from SPECT/CT imaging during 6 days post-tracer and 8 days post-therapy. Next, the OLINDA calculation was split over multiple time periods and summed to get the total dose, which accounted for the changes in tumor size. Results from the second calculation were compared with results determined by coupling SPECT/CT images with DPM Monte Carlo algorithms. Results from the OLINDA calculation accounting for changes in tumor size were almost always higher (median 22%, range -1%-68%) than the results from OLINDA using the baseline tumor volume because of tumor shrinkage. There was good agreement (median -5%, range -13%-2%) between the OLINDA results and the self-dose component from Monte Carlo calculations, indicating that tumor shape effects are a minor source of error when using the sphere model. However, because the sphere model ignores cross-irradiation, the OLINDA calculation significantly underestimated (median 14%, range 2%-31%) the total tumor absorbed dose compared with Monte Carlo. These results show that when the quantity of interest is the mean tumor absorbed dose, the unit density sphere model is a practical alternative to Monte Carlo for some applications. For applications requiring higher accuracy, computer-intensive Monte Carlo calculation is needed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90433/1/cbr-2E2011-2E0965.pd
Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study
Abstract Integrated systems combining functional (single-photon emission computed tomography; SPECT) imaging with anatomic (computed tomography; CT) imaging have the potential to greatly improve the accuracy of dose estimation in radionuclide therapy. In this article, we present the methodology for highly patient-specific tumor dosimetry by utilizing such a system and apply it to a pilot study of 4 follicular lymphoma patients treated with I-131 tositumomab. SPECT quantification included three-dimensional ordered-subset expectation-maximization reconstruction and CT-defined tumor outlines at each time point. SPECT/CT images from multiple time points were coupled to a Monte Carlo algorithm to calculate a mean tumor dose that incorporated measured changes in tumor volume. The tumor shrinkage, defined as the difference between volumes drawn on the first and last CT scan (a typical time period of 15 days) was in the range 5%-49%. The therapy-delivered mean tumor-absorbed dose was in the range 146-334cGy. For comparison, the therapy dose was also calculated by assuming a static volume from the initial CT and was found to underestimate this dose by up to 47%. The agreement between tracer-predicted and therapy-delivered tumor-absorbed dose was in the range 7%-21%. In summary, malignant lymphomas can have dramatic tumor regression within days of treatment, and advanced imaging methods allow for a highly patient-specific tumor-dosimetry calculation that accounts for this regression.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/78152/1/cbr.2008.0568.pd
Characterization of a gas detector prototype based on Thick-GEM for the MAGNEX focal plane detector
A new gas detector prototype for the upgrade of the focal plane detector of
the MAGNEX large-acceptance magnetic spectrometer has been developed and tested
in view of the NUMEN project. It has been designed to operate at low gas
pressure for detecting medium to heavy ions in the energy range between 15 and
60 AMeV. It is a drift chamber based on Multi-layer Thick-GEM (M-THGEM) as
electron multiplication technology. Tests with two different M-THGEM layouts
have been performed using both a radioactive -particle source and
accelerated heavy-ion beams. The characterization of the detector in terms of
measured currents that flow through the electrodes as a function of different
parameters, including applied voltages, gas pressure and rate of incident
particle, is described. The gain and ion backflow properties have been studied
SELIMETRY- a multicentre I-131 dosimetry trial: a clinical perspective
Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in resensitizing advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Patients deemed to have sufficient iodine uptake in previously iodine refractory lesions after 4 weeks of Selumetinib therapy will be given an empirical activity of 5.5 GBq I-131, and response to therapy will be assessed. The trial presents an opportunity to investigate the dosimetric aspects of radioiodine therapy for advanced thyroid cancer. Patients will undergo serial I-123 single-photon emission CT (SPECT)/CT scans following Selumetinib therapy to determine whether there has been a change in the degree of iodine uptake to justify further I-131 therapy, and to allow dosimetric calculations to predict absorbed dose to target lesions following therapy. Patients receiving I-131 therapy will undergo a further series of post-therapy SPECT/CT scans to allow dosimetric calculations. We describe the challenges in setting up a multicentre trial in a relatively underinvestigated field, describing the work that has been carried out to calibrate and validate measurements to ensure that standardized image data are collected at each site. We hope that this trial will lead to individualization and optimization of therapy for patients with advanced thyroid cancer and that the ground work carried out in setting up a network of centres capable of standardized molecular radiotherapy dosimetry will lead to further clinical trials in this field
- …